Disclosure Plus

Exchange Announces Intention to Designate INVENIA Co.,Ltd. as a Company with Inadequate Disclosure

Park Sun-Yeop
2026-07-15 18:04:27
[Edaily Reporter Park Sun-Yeop ] INVENIA Co.,Ltd.(079950)announced on the 15th that it has been notified of a pending designation as a company with inadequate disclosure practices because it failed to disclose that, during its internal financial settlement process, grounds for designation as a “monitored stock,” a “nominal delisting,” or a “substantive review of listing eligibility” had arisen.
The date on which the grounds for disclosure arose was February 11. The exchange plans to follow the relevant procedures and decide by August 10 whether to designate the company as a non-compliant discloser and determine the penalty points to be imposed.
INVENIA Co.,Ltd. currently has 0 penalty points imposed for non-compliant disclosures over the past year.
If the company is ultimately designated as a non-compliant discloser and the penalty points imposed for this incident total 8 or more, trading in its shares may be suspended for one day. If the cumulative penalty points over the past year, including this incident, total 10 or more, the company may be subject to a substantive review of its listing eligibility.

Economy

Corporation

IT·Science

Economy

SamsungElectronics Applies 2-Nanometer Process to HBM5… “Speed Improved by Over 50%”

SamsungElectronics will apply a Gate-All-Around (GAA)-based 2-nanometer foundry process to the base die of HBM5, its next-generation High Bandwidth Memory (HBM). Building on the mass production experi…
2026-07-27 09:33:11

Corporation

COWAY Expands Nationwide… Opens 10 'COWAY Galleries' in the First Half of This Year

Life solutions company COWAY(021240)announced on the 27th that it opened 10 new “COWAY Gallery” brand experience and retail stores in major commercial districts nationwide during the first half of thi…
2026-07-27 10:13:10

IT·Science

Huonslab Secures Patent for Subcutaneous ADC Formulation Incorporating the ‘HyDIFFUZE’ Platform

Huonslab announced on July 27 that it has secured a patent covering a subcutaneous (SC) formulation of an antibody-drug conjugate (ADC) incorporating its proprietary human-derived hyaluronidase-based …
2026-07-27 10:28:02